フラボノールおよびその類似剤によるアルツハイマー病の予防
George Uhl1, Balaji Kannan2, Joungil Choi3
1Department of Neurology, University of Maryland School of Medicine, Baltimore MD 21201, USA; Neurology and Research Services, VA Maryland Healthcare System, Baltimore MD 21201, USA; Department of Pharmacology, University of Maryland School of Medicine, Baltimore MD 21201, USA.
The journal of prevention of Alzheimer's disease
|September 4, 2025
まとめ
フラボノールの摂取量が増加すると,アルツハイマー病 (AD) と認知症のリスクが著しく低下します. この保護効果は,ADの遺伝的傾向が高い個体において特に顕著である.
科学分野:
- 栄養神経科学
- ゲロントロジー
- 薬理学について
背景:
- アルツハイマー病 (AD) は高齢者にとって重大な健康問題です
- 神経退行性疾患の予防における食事要因の役割はますます認識されています.
- 植物由来化合物のクラスであるフラボノールには 神経保護性があることが示されています
研究 の 目的:
- フラボノール摂取とアルツハイマー病 (AD) と認知症の発生率との関連を調査する.
- ADリスクにおける潜在的な遺伝子環境相互作用を調査する.
- フラボノールの神経保護効果の背後にあるメカニズムを特定する.
主な方法:
- 食中のフラボノール摂取量とAD/認知症の診断を調査した4つの観察研究のデータ分析.
- フラボノールの用量反応と構造活性パターンの評価
- フラボノールメカニズムに関する動物モデルとインビトロ研究からの証拠のレビュー
主要な成果:
- フラボノール (またはそのグリコシド) の食事摂取量が高いことは,AD/認知症の診断の発生率の減少と関連していました.
- 遺伝的に高リスクの個体でフラボノール摂取量が高く,ADリスクの大幅な減少 (約50%) が観察され,これは遺伝子と環境の相互作用を示しています.
- 利益は控えめから中等な消費レベルと特定のフラボノール構造に関連していました.
結論:
- 食事によるフラボノールの摂取は高齢者におけるADの発生率を減らすための有望で変更可能な戦略です.
- この発見は,ADの予防において遺伝的傾向と食事パターンを考慮することの重要性を強調しています.
- ADの緩和のためにフラボノール類似体とサプリメント戦略のさらなる研究が必要である.
関連する概念動画
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Cancer Prevention
6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.3K
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33


